501 related articles for article (PubMed ID: 26577689)
1. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
Acosta EG; Bartenschlager R
Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
[TBL] [Abstract][Full Text] [Related]
2. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
3. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
4. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis.
Gan ES; Ting DH; Chan KR
Expert Rev Anti Infect Ther; 2017 Feb; 15(2):111-119. PubMed ID: 27796143
[TBL] [Abstract][Full Text] [Related]
5. Immune correlates for dengue vaccine development.
Srikiatkhachorn A; Yoon IK
Expert Rev Vaccines; 2016; 15(4):455-65. PubMed ID: 26560015
[TBL] [Abstract][Full Text] [Related]
6. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():597. PubMed ID: 29740424
[TBL] [Abstract][Full Text] [Related]
8. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
9. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
10. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
11. Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.
Watanabe S; Chan KW; Wang J; Rivino L; Lok SM; Vasudevan SG
J Virol; 2015 Jun; 89(11):5847-61. PubMed ID: 25787279
[TBL] [Abstract][Full Text] [Related]
12. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
[TBL] [Abstract][Full Text] [Related]
14. The human antibody response to dengue virus infection.
Wahala WM; Silva AM
Viruses; 2011 Dec; 3(12):2374-95. PubMed ID: 22355444
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
[TBL] [Abstract][Full Text] [Related]
16. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
[TBL] [Abstract][Full Text] [Related]
17. The Interplay of Dengue Virus Morphological Diversity and Human Antibodies.
Lok SM
Trends Microbiol; 2016 Apr; 24(4):284-293. PubMed ID: 26747581
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
19. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults.
Saito Y; Moi ML; Takeshita N; Lim CK; Shiba H; Hosono K; Saijo M; Kurane I; Takasaki T
BMC Infect Dis; 2016 Oct; 16(1):578. PubMed ID: 27756212
[TBL] [Abstract][Full Text] [Related]
20. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope.
Metz SW; Thomas A; White L; Stoops M; Corten M; Hannemann H; de Silva AM
Virol J; 2018 Apr; 15(1):60. PubMed ID: 29609659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
